Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model

Multiple Sclerosis Journal-ETC

Aug 8

Written By Matthijs Versteegh

multiple sclerosis

Matthijs Versteegh

Budget impact and transferability of cost–effectiveness of DPYD testing in metastatic breast cancer in three health systems

Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale